Ardelyx Up 50% After Positive Phase 3 Study Of Tenapanor

Ardelyx Inc ARDX shares are trading higher by $2.63, or 48 percent, at $8.03 in Thursday's session.

After Wednesday's close, the company announced a pivotal phase 3 study of Tenapanor met its primary and secondary endpoints, supporting its NDA submission in 2018.

After a higher open, Ardelyx had a 70-cent retreat to $7.30 before continuing its move higher. The ensuing rally took the stock to $8.65. That high is just shy of its May 12 high ($8.80), which was the high for the session when it fell from its previous day's close of $12.45 to $7.45.

Interestingly, the company reported some positive results for Tenapanor at that time, but the results didn't meet the Streets expectations.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: TechnicalsIntraday UpdateMoversTrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!